大唐药业
(920433)
| 流通市值：8.96亿 | | | 总市值：13.54亿 |
| 流通股本：1.69亿 | | | 总股本：2.56亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 42,981,295.49 | 133,403,704.17 | 102,317,249.5 | 73,858,902.06 |
| 营业收入 | 42,981,295.49 | 133,403,704.17 | 102,317,249.5 | 73,858,902.06 |
| 二、营业总成本 | 39,737,876.88 | 213,454,416.1 | 150,712,037.99 | 99,538,721.68 |
| 营业成本 | 14,682,539.9 | 63,379,602.5 | 47,129,481.53 | 33,938,167.26 |
| 税金及附加 | 515,135.8 | 5,463,878.41 | 2,909,405.6 | 2,809,091.5 |
| 销售费用 | 12,513,350.15 | 92,523,965.97 | 63,675,966.48 | 39,927,219.1 |
| 管理费用 | 8,853,582.58 | 39,863,185.37 | 30,942,332.77 | 20,241,217.98 |
| 研发费用 | 2,596,096.83 | 12,535,870.81 | 7,074,051.58 | 4,261,025.28 |
| 财务费用 | 577,171.62 | -312,086.96 | -1,019,199.97 | -1,637,999.44 |
| 其中:利息费用 | 576,761.3 | -318,766.78 | -842,861.26 | -1,456,663.05 |
| 其中:利息收入 | 3,263.45 | 21,676.85 | 189,439.5 | 187,159.49 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 18,030.54 | 275,026.47 | 205,308.77 | 166,614.41 |
| 加:投资收益 | - | 536,002.96 | 407,051.72 | 308,868.06 |
| 资产减值损失(新) | -579,921.39 | -14,627,488.02 | -3,424,058.06 | -2,099,061.26 |
| 信用减值损失(新) | -482,831.67 | 751,649.1 | -1,632,221.07 | -1,069,329.88 |
| 其他收益 | 603,167.27 | 6,836,959.12 | 4,895,011.9 | 2,862,612.8 |
| 四、营业利润 | 2,801,863.36 | -86,278,562.3 | -47,943,695.23 | -25,510,115.49 |
| 加:营业外收入 | - | 40,000 | 467,605.96 | 246,500 |
| 减:营业外支出 | - | 543,066.45 | - | - |
| 五、利润总额 | 2,801,863.36 | -86,781,628.75 | -47,476,089.27 | -25,263,615.49 |
| 减:所得税费用 | 412,275.97 | -3,593,547.57 | -6,398,919.1 | -3,362,384.16 |
| 六、净利润 | 2,389,587.39 | -83,188,081.18 | -41,077,170.17 | -21,901,231.33 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 2,389,587.39 | -83,188,081.18 | -41,077,170.17 | -21,901,231.33 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 2,389,587.39 | -83,188,081.18 | -41,077,170.17 | -21,901,231.33 |
| 扣除非经常损益后的净利润 | 1,883,835.35 | -89,779,640.24 | -45,860,710.39 | -24,773,680.47 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | -0.33 | -0.16 | -0.09 |
| (二)稀释每股收益 | 0.01 | -0.33 | -0.16 | -0.09 |
| 九、综合收益总额 | 2,389,587.39 | -83,188,081.18 | -41,077,170.17 | -21,901,231.33 |
| 归属于母公司股东的综合收益总额 | 2,389,587.39 | -83,188,081.18 | -41,077,170.17 | -21,901,231.33 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-29 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |